85070-67-3

Basic information

• Product Name: 2-Fluoro-4-methylbenzonitrile
• Synonyms: 2-FLUORO-4-METHYLBENZONITRILE;Benzonitrile, 2-fluoro-4-methyl- (9CI);2-Fluoro-4-methylbenzonitrile 98%;2-Fluoro-4-methylbenzonitrile98%;2-Fluoro-4-methylbenzonitirile;2-Fluoro-4-methylben;4-Cyano-3-fluorotoluene;2-Fluoro-4-Methylbenzenecarbonitrile
• CAS NO: 85070-67-3
• Molecular Formula: C₈H₆FN
• Molecular Weight: 135.14
• EINECS: 285-407-3
• Product Categories: Fluorin-contained Benzonitrile series;NITRILE;Miscellaneous;Fluorine series
• Mol File: 85070-67-3.mol

Chemical Properties

• Melting Point: 52-53°C
• Boiling Point: 219.6 °C at 760 mmHg
• Flash Point: 93.3 °C
• Appearance: /
• Density: 1.11 g/cm³
• Vapor Pressure: 0.118mmHg at 25°C
• Refractive Index: 1.507
• Storage Temp.: Sealed in dry,Room Temperature
• Water Solubility: Insoluble in water, soluble in chloroform, acetone and other organic solvents.
• CAS DataBase Reference: 2-Fluoro-4-methylbenzonitrile(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Fluoro-4-methylbenzonitrile(85070-67-3)
• EPA Substance Registry System: 2-Fluoro-4-methylbenzonitrile(85070-67-3)

Safety Data

• Hazard Codes: T,Xi
• Statements: 37/38-41-36/37/38-20/21/22
• Safety Statements: 26-39-36/37-9
• RIDADR: UN3439
• HazardClass: 6.1
• PackingGroup: III
• Hazardous Substances Data: 85070-67-3(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
2-Fluoro-4-methylbenzonitrile is used as a key intermediate in the synthesis of fluorobenzamidrazone thrombin inhibitors. These inhibitors are important for the development of antithrombotic drugs, which are crucial in the treatment and prevention of blood clot-related disorders, such as deep vein thrombosis, pulmonary embolism, and stroke. The presence of the fluorine atom and the nitrile group in 2-Fluoro-4-methylbenzonitrile contributes to the enhanced potency and selectivity of the resulting thrombin inhibitors, making it a valuable component in the design and synthesis of novel antithrombotic agents.

InChI:InChI=1/C8H6FN/c1-6-2-3-7(5-10)8(9)4-6/h2-4H,1H3

Upstream product

• 452-74-4 4-bromo-3-fluorotoluene 
• 544-92-3 copper(I) cyanide 
• 452-80-2 2-fluoro-4-methylaniline 
• 151-50-8 potassium cyanide 
• 557-21-1 dicyanozinc 
• 144-55-8 sodium hydrogencarbonate 

Downstream Products

• 222978-03-2 4-cyano-3-fluorobenzylbromide 
• 440105-58-8 α,α-dibromo-4-cyano-3-fluorotoluene 
• 1061518-30-6 C₁₆H₁₅FN₂O₂ 
• 1097871-99-2 (4-cyano-3-fluorophenyl)acetic acid 
• 882679-89-2 2-fluoro-3-iodo-4-methylbenzoic acid 
• 909185-87-1 2-fluoro-3-iodo-4-methylbenzaldehyde 
• 1067904-88-4 (2-fluoro-3-iodo-4-methylphenyl)methanol 
• 909185-89-3 N-cyclopropyl-2-fluoro-N'-hydroxy-3-iodo-4-methylbenzamidine 
• 1268351-46-7 2-fluoro-3-iodo-4-methylbenzaldehyde oxime 
• 1338065-48-7 C₁₄H₁₈N₂O 
• 1338065-47-6 C₁₁H₁₄N₂O 
• 1247238-62-5 (4-(dimethylamino)-2-(piperidin-1-yl)phenyl)methanamine 
• 1248232-73-6 (4-methyl-2-pyrrolidin-1-yl-phenyl)methanamine 
• 1338065-30-7 1-[(4-methyl-2-pyrrolidin-1-yl-phenyl)methyl]-3-(3-oxo-4H-1,4-benzoxazin-8-yl)urea 

Relevant articles and documents

New 7-phenyl-[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one derivatives

This invention is directed to new inhibitors of the p38 mitogen-activated protein kinase having the general formula (I), to pharmaceutical compositions comprising them, and to their use in therapy.

NEW 7-PHENYL-[1,2,4]TRIAZOLO[4,3-A]PYRIDIN-3(2H)-ONE DERIVATIVES

This invention is directed to new inhibitors of the p38 mitogen-activated protein kinase having the general formula (I), to processes for their preparation, to pharmaceutical compositions comprising them, and to their use in therapy.

NITROGEN-CONTAINING BICYCLIC HETEROARYL COMPOUNDS AND METHODS OF USE

The present invention comprises a new class of compounds capable of modulating Raf kinase and, accordingly, useful for treatment of Raf kinase mediated diseases, including melanomas, tumors and other cancer-related conditions. The compounds have Formula (I) wherein R1 is Formula (II), (III) or (IV) and A1, A2, A3, A4, X, Z, Z', R1, R2, R3, R4, R5 and R6 are defined herein. The invention further comprises pharmaceutical compositions, methods for treatment of Raf kinase mediated diseases, and intermediates and processes useful for the preparation of compounds of the invention.

Methods of making 2,6-diaryl piperidine derivatives

Methods for preparing 2,6-diaryl piperidine derivatives are described. More particularly, 2,6-diaryl piperidines having formula 1-4 are prepared by cyclocondensation of an aryl or heteroaryl aldehyde with 1,3-acetonedicarboxylic acid.

A fluorine scan of the phenylamidinium needle of tricyclic thrombin inhibitors: Effects of fluorine substitution on pKa and binding affinity and evidence for intermolecular C-F...CN interactions

The H-atoms of the phenylamidinium needle of tricyclic thrombin inhibitors, which interacts with Asp189 at the bottom of the selectivity pocket S1 of the enzyme, were systematically exchanged with F-atoms in an attempt to improve the pharmacokinetic prope

Substituted polycyclic aryl and heteroaryl pyrazinones useful for selective inhibition of the coagulation cascade

The invention relates to substituted polycyclic aryl and heteroaryl pyrazinone compounds useful as inhibitors of serine proteases of the coagulation cascade and compounds, compositions and methods for anticoagulant therapy for the treatment and prevention of a variety of thrombotic conditions including coronary artery and cerebrovascular diseases.

Efficacious and orally bioavailable thrombin inhibitors based on a 2,5-thienylamidine at the P1 position: Discovery of N-carboxymethyl-D-diphenylalanyl-L-prolyl[(5-amidino-2- thienyl)methyllamide

Thrombin, a crucial enzyme in the blood coagulation, has been a target for antithrombotic therapy. Orally active thrombin inhibitors would provide effective and safe prophylaxis for venous and arterial thrombosis. We conducted optimization of a highly efficacious benzamidine-based thrombin inhibitor LB30812 (3, Ki = 3 pM) to improve oral bioavailability. Of a variety of arylamidines investigated at the P1 position, 2,5-thienylamidine effectively replaced the benzamidine without compromising the thrombin inhibitory potency and oral absorption. The sulfamide and sulfonamide derivatization at the N-terminal position in general afforded highly potent thrombin inhibitors but with moderate oral absorption, while the well-absorbable N-carbamate derivatives exhibited limited metabolic stability in S9 fractions. The present work culminated in the discovery of the N-carboxymethyl- and 2,5-thienylamidine-containing compound 22 that exhibits the most favorable profiles of anticoagulant and antithrombotic activities as well as oral bioavilability (Ki = 15 pM; F = 43%, 42%, and 15% in rats, dogs, and monkeys, respectively). This compound on a gravimetric basis was shown to be more effective than a low molecular weight heparin, enoxaparin, in the venous thrombosis models of rat and rabbit. Compound 22 (LB30870) was therefore selected for further preclinical and clinical development.

INHIBITORS OF PRENYL-PROTEIN TRANSFERASE

The present invention is directed to peptidomimetic piperazine-containing macrocyclic compounds which inhibit prenyl-protein transferase and the prenylation of the oncogene protein Ras. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for inhibiting prenyl-protein transferase and the prenylation of the oncogene protein Ras

Orally available peptidic thrombin inhibitors

The present invention relates to novel thrombin inhibitors that are useful as anticoagulants. More particularly, the present invention is directed to peptide derivatives having high antithrombotic activity and high oral bioavailability.

Non-covalent thrombin inhibitors featuring P3-heterocycles with P1-bicyclic arginine surrogates

Novel, potent, and highly selective classes of thrombin inhibitors were identified, which resulted from judicious combination of P4-aromatics and P2-P3-heterocyclic dipeptide surrogates with weakly basic (calcd pKa ～non-basic - 8.6) bicyclic P1-arginine mimics. The design, synthesis, and biological activity of achiral, non-covalent, orally bioavailable inhibitors NC1-NC44 featuring P1-indazoles, benzimidazoles, indoles, benzotriazoles, and aminobenzisoxazoles is disclosed.